Equities research analysts forecast that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will post $38.56 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Ultragenyx Pharmaceutical’s earnings. The lowest sales estimate is $33.85 million and the highest is $42.80 million. Ultragenyx Pharmaceutical reported sales of $18.17 million during the same quarter last year, which indicates a positive year over year growth rate of 112.2%. The business is expected to report its next earnings report on Monday, May 4th.
According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full year sales of $181.56 million for the current financial year, with estimates ranging from $149.10 million to $201.90 million. For the next year, analysts anticipate that the firm will report sales of $291.79 million, with estimates ranging from $201.90 million to $345.13 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.61) by ($0.01). Ultragenyx Pharmaceutical had a negative return on equity of 49.81% and a negative net margin of 388.30%. The firm had revenue of $35.59 million for the quarter, compared to analysts’ expectations of $32.31 million.
Shares of NASDAQ:RARE traded up $0.45 during midday trading on Friday, hitting $61.55. 326,935 shares of the stock were exchanged, compared to its average volume of 573,631. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.64 and a current ratio of 6.79. Ultragenyx Pharmaceutical has a 52-week low of $35.41 and a 52-week high of $74.50. The business’s fifty day simple moving average is $55.70 and its two-hundred day simple moving average is $47.86. The company has a market capitalization of $3.54 billion, a PE ratio of -8.64 and a beta of 2.35.
In other Ultragenyx Pharmaceutical news, SVP Theodore Alan Huizenga sold 1,000 shares of the stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $61.00, for a total transaction of $61,000.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 7.80% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Capital World Investors grew its position in shares of Ultragenyx Pharmaceutical by 36.5% in the fourth quarter. Capital World Investors now owns 3,237,295 shares of the biopharmaceutical company’s stock valued at $138,265,000 after purchasing an additional 865,865 shares during the last quarter. Orbimed Advisors LLC grew its position in shares of Ultragenyx Pharmaceutical by 948.0% in the third quarter. Orbimed Advisors LLC now owns 834,313 shares of the biopharmaceutical company’s stock valued at $35,692,000 after purchasing an additional 754,706 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Ultragenyx Pharmaceutical by 154.8% in the fourth quarter. Franklin Resources Inc. now owns 370,650 shares of the biopharmaceutical company’s stock valued at $15,830,000 after purchasing an additional 225,200 shares during the last quarter. Alliancebernstein L.P. grew its position in shares of Ultragenyx Pharmaceutical by 15.8% in the fourth quarter. Alliancebernstein L.P. now owns 1,547,393 shares of the biopharmaceutical company’s stock valued at $66,089,000 after purchasing an additional 211,635 shares during the last quarter. Finally, EcoR1 Capital LLC grew its position in shares of Ultragenyx Pharmaceutical by 324.9% in the fourth quarter. EcoR1 Capital LLC now owns 261,554 shares of the biopharmaceutical company’s stock valued at $11,171,000 after purchasing an additional 200,000 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Further Reading: FinTech
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.